Blautix
Alternative Names: CJRB-205; MRx-1234Latest Information Update: 19 Sep 2023
At a glance
- Originator 4D Pharma PLC
- Class Anti-inflammatories; Bacteria; Irritable bowel syndrome therapies
- Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Irritable bowel syndrome
Most Recent Events
- 19 Sep 2023 Phase-II development is still ongoing for Irritable bowel syndrome in United Kingdom, USA, Poland and Ireland (CJ Biosciences pipeline, September 2023)
- 06 May 2023 Efficacy data from phase II trial in Irritable bowel syndrome was presented at Digestive Disease Week 2023 (DDW-2023)
- 27 Mar 2023 CJ Biosciences acquires Blautix from 4D Pharma (CJ Biosciences pipeline, September 2023)